Trial Profile
A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 28 Feb 2024
Price :
$35
*
At a glance
- Drugs Tapotoclax (Primary) ; Azacitidine; Itraconazole
- Indications Acute myeloid leukaemia; Multiple myeloma
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Amgen
- 23 Feb 2024 Planned End Date changed from 12 Sep 2024 to 28 Jun 2024.
- 23 Feb 2024 Planned primary completion date changed from 12 Sep 2024 to 28 Jun 2024.
- 19 Feb 2024 Planned End Date changed from 25 Jul 2024 to 12 Sep 2024.